Focal Segmental Glomerulosclerosis clinical trials at UC Davis

• Experimental Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

  open to eligible people ages 1-40

  This is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in children and adults.

  Minneapolis, Minnesota

Last updated: September 2, 2020